Clinical trials: Uremia
Hemolytic Uremic Syndrome of Childhood
Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHU
The investigators aim to perform the first controlled randomized prospective study using ECZ in pediatric STEC-HUS. This is of great interest as there is still no efficient specific therapy in that potentially devastating…
- Trial name
- ECULISHU (NCT02205541)
- Testing
- Eculizumab
- Where
- 18 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Toulouse
Atypical Hemolytic Uremic Syndrome(aHUS)
A Prospective, Non-interventional, Observational Study of Presentation, Treatment Patterns and Outcomes in Atypical Hemolytic Uremic Syndrome Patients
This is a China, non-interventional, observational study and will follow the Good Phar-macoepidemiology Practices guidelines. This study will enrol paediatric and adult patients diagnosed with aHUS who will be treated according…
- Trial name
- NCT06099236
- Where
- 26 sites in China
- Volunteers
- 367 people
- Sponsor
- AstraZeneca
Atypical Hemolytic Uremic Syndrome
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
This study aims to evaluate the efficacy and safety of crovalimab in pediatric participants with aHUS.
- Trial name
- COMMUTE-p (NCT04958265)
- Testing
- Crovalimab
- Where
- 20 sites in United States, Belgium and 8 more
- Volunteers
- 41 people
- Sponsor
- Hoffmann-La Roche
Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis
Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases
This project aims to identify, through RNA-Seq technology, the genetic alterations underlying undiagnosed rare diseases in pediatric and adult patients with early onset and with negative WES.
- Conditions
- Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, Autosomal Dominant Polycystic Kidney, Healthy
- Trial name
- ANTHEM (NCT05996731)
- Testing
- Skin biopsy
- Where
- Italy
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Mario Negri Institute for Pharmacological Research
Hemolytic-Uremic Syndrome, Anemia
Erythropoietin in Hemolytic Uremic Syndrome
This study will evaluate the impact of early administration of erythropoietin in the number of red blood cell transfusions in children with Shiga toxin-producing Escherichia coli hemolytic uremic syndrome (STEC-HUS).
- Trial name
- NCT03776851
- Testing
- erythropoietin
- Where
- Argentina
- Volunteers
- 24 people
- Sponsor
- Hospital General de Niños Pedro de Elizalde
Hemolytic Uremic Syndrome, Hemorrhagic Colitis
Study of Repetitive Intestinal Lavage in Patients With EHEC Associated Hemorrhagic Colitis
The investigators examined the outcome of patients with severe Enterohaemorrhagic E. Coli (EHEC) O104:H4 infection suffering from bloody diarrhoea that were at risk to develop hemolytic uremic syndrome and underwent repetitive…
- Conditions
- Hemolytic Uremic Syndrome, Hemorrhagic Colitis, Intestinal Infectious Disease, Intestinal Infection Due to E. Coli
- Trial name
- EHEC-PEG (NCT01561248)
- Testing
- polyethylene glycol solution for daily bowel lavage.
- Where
- Germany
- Volunteers
- 33 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome
Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients
Hematopoietic stem cell transplantation (HCT)-associated thrombotic microangiopathy (TMA) is an understudied complication of HCT that significantly affects transplant related morbidity and mortality.
- Conditions
- Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome, Multiple Organ Dysfunction Syndrome
- Trial name
- NCT03518203
- Testing
- Eculizumab
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Atypical Hemolytic Uremic Syndrome
Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS
The purpose of this study is to determine whether eculizumab is safe and effective in the treatment of adolescent patients with plasma therapy-resistant Atypical Hemolytic-Uremic Syndrome (aHUS).
- Trial name
- aHUS (NCT00844844)
- Testing
- Eculizumab
- Where
- 17 sites in United States, Austria and 3 more
- Volunteers
- 1 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Pancreas Transplant, Type 1 Diabetes Mellitus
Pancreas Transplant Alone in Uremia and Non-uremia Patients
Theoretically, pancreas transplant alone in uremia (PTAu) or pancreas before kidney transplant (PBK) may be considered for patients awaiting both pancreas and kidney grafts, alongside options like simultaneous pancreas-kidney…
- Conditions
- Pancreas Transplant, Type 1 Diabetes Mellitus, Uremia
- Trial name
- PTAu (NCT07872800)
- Testing
- pancreas transplant
- Where
- Taiwan
- Volunteers
- 184 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis
National Registry of Rare Kidney Diseases
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research.
- Conditions
- Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis, AHL Amyloidosis, AL Amyloidosis
- Trial name
- RaDaR (NCT06065852)
- Where
- United Kingdom
- Volunteers
- 35,000 people
- Sponsor
- UK Kidney Association
Hemolytic-Uremic Syndrome
Shiga Toxin Producing Escherichia Coli (STEC) Volume Expansion
This study will provide feasibility data regarding the conduct of a clinical trail evaluating the use of early aggressive inpatient intravenous rehydration in children with Shiga Toxin producing E. coli infection.
- Trial name
- NCT03275792
- Testing
- D5-0.9%NS, Routine home oral rehydration
- Where
- Canada
- Sponsor
- University of Calgary
Atypical Hemolytic Uremic Syndrome
The Burden of Atypical Hemolytic Uremic Syndrome and The Clinical Characteristics of Patients in Egyptian Hospitals A Multicenter, Observational, Retrospective Cohort Study in Egypt
Atypical hemolytic uremic syndrome (aHUS) is a rare, progressive, and life-threatening disease that occurs at any age, with incidence rate of 0.75 to 2.0 cases per million population per year.
- Trial name
- REACH (NCT07218536)
- Where
- 6 sites in Egypt
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Hemolytic Uremic Syndrome
Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated Hemolytic Uremic Syndrome
OBJECTIVES: I. Determine the effect of SYNSORB Pk therapy on mortality and frequency of severe extrarenal complications observed in children with acute stage E. coli-associated hemolytic uremic syndrome. II.
- Trial name
- NCT00004465
- Testing
- SYNSORB Pk
- Where
- 27 sites in United States, Canada
- Volunteers
- 145 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Atypical Hemolytic Uremic Syndrome (aHUS)
Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
The purpose of the study is to assess the safety and efficacy of ravulizumab to control disease activity in adolescent and adult participants with aHUS who had not previously used a complement inhibitor.
- Trial name
- NCT02949128
- Testing
- Ravulizumab
- Where
- 37 sites in United States, Australia and 12 more
- Volunteers
- 58 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Peritonitis, Malnutrition
Probiotics Use in the Chronic Peritoneal Dialysis Patients
The purpose of this study is to determine whether probiotics can improve the nutrition status and prevent peritonitis in the chronic peritoneal dialysis patients.
- Trial name
- NCT01076426
- Testing
- Pro-biotics, Oligosaccharide
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Cheng-Kung University Hospital
Hemolytic-Uremic Syndrome, Membranoproliferative Glomerulonephritis
New Analytic Tools for aHUS and C3G Diagnosis
This protocol is part of a larger project, COMPRare (COMPlement-mediated Rare kidney diseases), which has been financed on behalf of the EJP RD (European Joint Programme on Rare Diseases) program of EU and is leaded by a…
- Conditions
- Hemolytic-Uremic Syndrome, Membranoproliferative Glomerulonephritis, Healthy
- Trial name
- COMPRare (NCT05985122)
- Testing
- C3NEF assay
- Where
- Italy
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Mario Negri Institute for Pharmacological Research
Atypical Hemolytic-Uremic Syndrome
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
Post-marketing safety data on patients treated and untreated with eculizumab or ravulizumab.
- Trial name
- NCT01522183
- Where
- 141 sites in United States, Australia and 15 more
- Volunteers
- 3,000 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Urea in Blood; High
Antibacterial Activity of Urea Against Ocular Bacteria
Antibacterial properties of urea was tested against 35 isolates from ocular infections.
- Trial name
- NCT04020406
- Testing
- Antibacterial Activity
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Assiut University
Thrombotic Thrombocytopenic Purpura, Atypical Hemolytic Uremic Syndrome
TTP and aHUS in Complicated Pregnancies
A single site observational study aiming to: (i) Identify cases of previously undiagnosed thrombotic thrombocytopenic purpura (TTP) and atypical haemolytic syndrome (aHUS) in a cohort of women with complicated pregnancies (ii)…
- Conditions
- Thrombotic Thrombocytopenic Purpura, Atypical Hemolytic Uremic Syndrome, Pre-Eclampsia, HELLP Syndrome
- Trial name
- NCT03605511
- Testing
- ADAMTS 13, complement and angiogenic biomarkers
- Where
- United Kingdom
- Volunteers
- 150 people
- Sponsor
- University College, London
Bloody Diarrhea, STEC, Unspecified
Phase 2/3 Study to Evaluate PK, Safety & Efficacy of INM004 in STEC Positive Pediatric Patients for Prevention of HUS
The investigational medicinal product (IMP), INM004, proposes to neutralize the toxin in the bloodstream to prevent the interaction of the Stx with the specific receptor, by means of a polyclonal antibody to be administered upon…
- Conditions
- Bloody Diarrhea, STEC, Unspecified, Hemolytic-Uremic Syndrome, Pediatric Kidney Disease
- Trial name
- NCT04132375
- Testing
- INM004
- Where
- 7 sites in Argentina
- Volunteers
- 11 people
- Sponsor
- Inmunova S.A.